- Home
- BMRA vs NRXS Comparison
BMRA vs NRXS Comparison
Compare BMRA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- NRXS
- Stock Information
- Founded
- BMRA 1971
- NRXS 2011
- Country
- BMRA United States
- NRXS United States
- Employees
- BMRA N/A
- NRXS N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NRXS
- Sector
- BMRA Health Care
- NRXS
- Exchange
- BMRA Nasdaq
- NRXS Nasdaq
- Market Cap
- BMRA 11.2M
- NRXS 12.5M
- IPO Year
- BMRA N/A
- NRXS 2023
- Fundamental
- Price
- BMRA $3.54
- NRXS $2.40
- Analyst Decision
- BMRA
- NRXS
- Analyst Count
- BMRA 0
- NRXS 0
- Target Price
- BMRA N/A
- NRXS N/A
- AVG Volume (30 Days)
- BMRA 43.6K
- NRXS 36.9K
- Earning Date
- BMRA 04-14-2025
- NRXS 05-21-2025
- Dividend Yield
- BMRA N/A
- NRXS N/A
- EPS Growth
- BMRA N/A
- NRXS N/A
- EPS
- BMRA N/A
- NRXS N/A
- Revenue
- BMRA $5,678,000.00
- NRXS $2,685,925.00
- Revenue This Year
- BMRA N/A
- NRXS $138,883.78
- Revenue Next Year
- BMRA N/A
- NRXS $118.59
- P/E Ratio
- BMRA N/A
- NRXS N/A
- Revenue Growth
- BMRA 5.01
- NRXS 9.18
- 52 Week Low
- BMRA $1.92
- NRXS $1.33
- 52 Week High
- BMRA $10.16
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- BMRA 39.79
- NRXS 65.87
- Support Level
- BMRA $3.18
- NRXS $1.33
- Resistance Level
- BMRA $3.93
- NRXS $2.09
- Average True Range (ATR)
- BMRA 0.47
- NRXS 0.36
- MACD
- BMRA -0.05
- NRXS 0.06
- Stochastic Oscillator
- BMRA 20.00
- NRXS 90.95
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).